title: Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes.
abstract: In order to characterize neuropeptide Y (NPY) receptors present in human adipocytes, we used selective ligands together with specific molecular probes able to recognize the different NPY receptor subtypes. RT-PCR experiments revealed the presence of Y(1) receptor transcripts with Y(4) and Y(5) and absence of Y(2) signals. Binding studies, using selective radioiodinated ligands, detected a high number (B(max)=497+/-124 fmol/mg protein) of a high affinity binding site only with [(125)I]peptide YY (PYY) and [(125)I](Leu(31), Pro(34))PYY. These sites exhibited a typical Y(1) profile as indicated by the rank order of affinity of NPY analogs and the high affinity of two selective NPY receptor antagonists, SR120819A and BIBP3226. In [(35)S]GTPgammaS binding experiments, PYY activation was totally inhibited by SR120819A and BIBP3226. Both compounds antagonized, with similar efficiency, the antilipolytic effect exerted by NPY in isolated adipocytes. Finally, PYY and Y(1) ligands enhanced adipocyte leptin secretion, an effect totally prevented by SR120819A. Thus, highly expressed in human adipocytes, the Y(1) receptor sustains the strong antilipolytic effect of NPY and exerts a positive action on leptin secretion.
authors.affiliation: Sanofi-Synthelabo, Toulouse, France. claudine.serradeil@sanofi-synthelabo.fr
authors.forename: C
authors.initials: C
authors.lastname: Serradeil-Le Gal
authors.forename: M
authors.initials: M
authors.lastname: Lafontan
authors.forename: D
authors.initials: D
authors.lastname: Raufaste
authors.forename: J
authors.initials: J
authors.lastname: Marchand
authors.forename: B
authors.initials: B
authors.lastname: Pouzet
authors.forename: P
authors.initials: P
authors.lastname: Casellas
authors.forename: M
authors.initials: M
authors.lastname: Pascal
authors.forename: J P
authors.initials: JP
authors.lastname: Maffrand
authors.forename: G
authors.initials: G
authors.lastname: Le Fur
mesh_terms: D017667:Adipocytes / Q000378:metabolism*; D000328:Adult; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001665:Binding Sites; D002462:Cell Membrane / Q000378:metabolism; D002478:Cells, Cultured; D018076:DNA, Complementary / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism; D006801:Humans; D020738:Leptin / Q000378:metabolism*; D008024:Ligands; D008066:Lipolysis; D008875:Middle Aged; D009281:Naphthalenes / Q000494:pharmacology; D010455:Peptides / Q000378:metabolism; D011485:Protein Binding; D011759:Pyrrolidines / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D054411:Receptors, Leptin; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors / Q000737:chemistry*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014158:Transcription, Genetic
chemical_list: C092926:BIBP 3226; D018076:DNA, Complementary; C515448:LEPR protein, human; D020738:Leptin; D008024:Ligands; D009281:Naphthalenes; D010455:Peptides; D011759:Pyrrolidines; D012333:RNA, Messenger; D054411:Receptors, Leptin; D017476:Receptors, Neuropeptide Y; C093150:SR 120819A; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D001120:Arginine